<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04212793</url>
  </required_header>
  <id_info>
    <org_study_id>UMCG 201800170</org_study_id>
    <nct_id>NCT04212793</nct_id>
  </id_info>
  <brief_title>Detection of PitNET Tissue During TSS Using Bevacizumab-800CW</brief_title>
  <acronym>DEPARTURE</acronym>
  <official_title>Detection of Pituitary Neuroendocrine Tumor (PitNET) Tissue During Endoscopic Transsphenoidal Surgery Using Bevacizumab-800CW</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a need for improved visualization of presence and extent of pituitary neuroendocrine
      tumor (PitNET) tissue during transsphenoidal surgery (TSS), especially in tumors invading the
      cavernous sinus (CS). Optical molecular imaging of PitNET associated biomarkers is a
      promising technique to accommodate this need. Vascular Endothelial Growth Factor (VEGF-A) is
      overexpressed in PitNET tissue compared to normal pituitary tissue and has proven to be a
      valid target for molecular imaging. Bevacizumab is an antibody that binds VEGF-A. By
      conjugating a fluorescent dye to this antibody, the fluorescent tracer molecule
      bevacizumab-800CW is created, which binds to VEGF-A. The investigators hypothesize that
      bevacizumab-800CW accumulates in PitNET tissue, enabling visualization using a molecular
      fluorescence endoscopy system. In this pilot intervention study the investigators will
      determine the feasibility of using microdoses (4.5, 10 and 25 mg) of bevacizumab-800CW to
      detect PitNET tissue intraoperatively.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study is a non-randomized, non-blinded, prospective, single center, pilot dose-finding study.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Discrimination of tumorous and non-tumorous tissue based on in vivo and ex vivo fluorescence measurements from bevacizumab-800CW gained during fluorescence endoscopic transsphenoidal surgery of pituitary neuroendocrine tumors (PitNETs)</measure>
    <time_frame>Three days after tracer injection</time_frame>
    <description>To determine the sensitivity of the marker bevacizumab-800CW in discriminating between tumorous and non-tumorous tissue during endoscopic transsphenoidal surgery of pituitary neuroendocrine tumors (PitNETs) defined as the tumor to background ratio and intrinsic fluorescence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events (AE), serious adverse events (SAE) and suspected unexpected serious adverse reactions (SUSAR)</measure>
    <time_frame>Up to 7 days after tracer injection</time_frame>
    <description>Data collection as a measure of safety and tolerability regarding administration of bevacizumab-800CW</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The correlation of in vivo and ex vivo fluorescent signals to histopathological analysis results</measure>
    <time_frame>Up to 1,5 year</time_frame>
    <description>Correlate the H/E images to the fluorescent images made with multiple ex vivo imaging modalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of the fluorescent signal by MDSFR/SFF spectroscopy</measure>
    <time_frame>Up to 1,5 year</time_frame>
    <description>Multi-diameter single-fiber reflectance with single-fiber fluorescence (MDSFR/SFF) spectroscopy can measure the fluorescence signal quantitatively, both in vivo and ex vivo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the (sub)-cellular distribution of bevacizumab-800CW by ex vivo fluorescence microscopy</measure>
    <time_frame>Up to 1,5 year</time_frame>
    <description>Imaging of the distribution of bevacizumab-800CW with a fluorescence microscope</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Pituitary Tumor</condition>
  <condition>Pituitary Adenoma</condition>
  <condition>Pituitary Macroadenoma</condition>
  <arm_group>
    <arm_group_label>NIR endoscopic TSS with 4.5 mg bevacizumab-800CW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIR endoscopic TSS with 10 mg bevacizumab-800CW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIR endoscopic TSS with 25 mg bevacizumab-800CW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab-IRDye800CW</intervention_name>
    <description>Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to endoscopic transsphenoidal surgery</description>
    <arm_group_label>NIR endoscopic TSS with 10 mg bevacizumab-800CW</arm_group_label>
    <arm_group_label>NIR endoscopic TSS with 25 mg bevacizumab-800CW</arm_group_label>
    <arm_group_label>NIR endoscopic TSS with 4.5 mg bevacizumab-800CW</arm_group_label>
    <other_name>Tracer administration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Molecular Fluorescence Endoscopy platform</intervention_name>
    <description>A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the Surgvision explorer endoscope. During surgery, three imaging moments are defined in which the fluorescence molecular endoscopy system will detect the fluorescent signal</description>
    <arm_group_label>NIR endoscopic TSS with 10 mg bevacizumab-800CW</arm_group_label>
    <arm_group_label>NIR endoscopic TSS with 25 mg bevacizumab-800CW</arm_group_label>
    <arm_group_label>NIR endoscopic TSS with 4.5 mg bevacizumab-800CW</arm_group_label>
    <other_name>Fluorescence endoscopy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with an established diagnosis of PitNET with a Knosp grade of 3 or 4 who are
             scheduled to undergo TSS.

          -  WHO performance status 0-2

          -  Signed written informed consent

        Exclusion Criteria:

          -  Medical or psychiatric conditions that compromise the patient's ability to give
             informed consent

          -  Pregnant or lactating women. Documentation of a negative pregnancy test must be
             available for woman of childbearing potential. Woman of childbearing potential are
             pre- menopausal women with intact reproductive organs and women less than two years
             after menopause

          -  History of infusion reactions to bevacizumab or other monoclonal antibody therapies.

          -  Inadequately controlled hypertension with or without current antihypertensive
             medication

          -  Within 6 months prior to inclusion: myocardial infarction, TIA, CVA, pulmonary
             embolism, uncontrolled chronic hepatic failure, unstable angina pectoris
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerrit van den Berg, PhD</last_name>
    <phone>+31503613430</phone>
    <email>g.van.den.berg@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark R Postma, MD</last_name>
    <phone>+31503618675</phone>
    <email>m.r.postma01@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Gerrit van den Berg, PhD</last_name>
      <phone>+31503613430</phone>
      <email>g.van.den.berg@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Mark R Postma, MD</last_name>
      <phone>+31503618675</phone>
      <email>m.r.postma01@umcg.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>December 24, 2019</last_update_submitted>
  <last_update_submitted_qc>December 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Dr. G. van den Berg</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

